These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 6988262)

  • 1. Continuous subcutaneous insulin infusion: a developing tool in diabetes research.
    Pickup JC; Keen H
    Diabetologia; 1980 Jan; 18(1):1-4. PubMed ID: 6988262
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical application of pre-programmed insulin infusion: continuous subcutaneous insulin therapy with a portable infusion system.
    Pickup JC; Viberti GC; Keen H; Parsons JA; Alberti KG
    Horm Metab Res Suppl; 1979; (8):202-4. PubMed ID: 395081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood glucose monitoring and computer regulation by means of an artificial endocrine pancreas.
    Kruse-Jarres JD; Braun G; Naegele R; Bresch M; Lehmann U
    Horm Metab Res Suppl; 1979; (8):42-5. PubMed ID: 395088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of cortisol circadian variations on insulin need and delivery in insulin-dependent diabetics. Assessment by the artificial beta cell.
    Altomare E; Moulin JP; Tavares S; Bourelly N; Lassmann V; Vague P
    Horm Metab Res Suppl; 1979; (8):110-5. PubMed ID: 395065
    [No Abstract]   [Full Text] [Related]  

  • 5. Control algorithms for artificial beta cell.
    Clemens AH
    Horm Metab Res Suppl; 1979; (8):35-8. PubMed ID: 395086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a closed-loop artificial pancreas.
    Kraegen EW; Whiteside R; Bell D; Chia YO; Lazarus L
    Horm Metab Res Suppl; 1979; (8):38-42. PubMed ID: 395087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspects of continuous subcutaneous insulin infusion (CSII) in diabetes.
    Keen H; Pickup JC; Viberti GC; Bilous R; Williams G
    Diabetes Care; 1981; 4(1):54-7. PubMed ID: 7009115
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of a perfusion syringe (Mill Hill Infusor) and a glucose-controlled insulin infusion system in the regulation of diabetes mellitus.
    Stavljenić A; Granić M; Topić B; Skrabalo Z
    Horm Metab Res Suppl; 1979; (8):207-11. PubMed ID: 395083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of daily insulin requirements in diabetics with an artificial endocrine pancreas.
    Lambert AE; Buysschaert M; Lambotte L
    Horm Metab Res Suppl; 1979; (8):120-7. PubMed ID: 395067
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of glucose-controlled insulin infusion system for improvement of subcutaneous insulin regimen.
    Irsigler K; Kritz H; Kaspar L; Brändle J; Franetzki M
    Horm Metab Res Suppl; 1979; (8):134-40. PubMed ID: 395070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The artificial beta cell (Biostator) in the adjustment of instable diabetics--results after 20 months.
    Beyer J; Wolf E; Cordes U; Hassingen W
    Horm Metab Res Suppl; 1979; (8):127-31. PubMed ID: 395068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin responses to mixed meals: comparison of an artificial beta cell and normal beta cells.
    Horwitz DL
    Horm Metab Res Suppl; 1979; (8):68-71. PubMed ID: 395093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substitution of islet cell function by mechanical device: extracorporeal artificial pancreas.
    Pfeiffer EF; Kerner W; Beischer W
    Adv Exp Med Biol; 1979; 119():501-8. PubMed ID: 386732
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of an artificial beta cell in surgery.
    Horwitz DL; Schwartz SS
    Horm Metab Res Suppl; 1979; (8):156-8. PubMed ID: 395072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Present and future expectations regarding insulin infusion systems.
    Marliss EB; Caron D; Albisser AM; Zinman B
    Diabetes Care; 1981; 4(2):325-7. PubMed ID: 7011751
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimal blood sugar control in labile diabetics using a portable open-loop insulin infusion system with a flexible program.
    Froesch ER; Blatter G; Morell B
    Horm Metab Res Suppl; 1979; (8):198-201. PubMed ID: 395079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of insulin infusion kinetics of an artificial beta cell on blood glucose control in insulin-dependent diabetics.
    Kerner W; Beischer W; Maier V; Pfeiffer EF
    Horm Metab Res Suppl; 1979; (8):71-80. PubMed ID: 395094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin treatment and state of control before, during, and after connection to a glucose controlled insulin infusion system (Biostator).
    Christiansen JS; Svendsen PA; Deckert T
    Horm Metab Res Suppl; 1979; (8):131-4. PubMed ID: 395069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substitution of islet-cell function with "open-loop" insulin infusion systems.
    Hepp KD; Renner R; Franetzki M; Mehnert H
    Adv Exp Med Biol; 1979; 119():485-9. PubMed ID: 386731
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term, ambulatory, subcutaneous insulin infusion versus multiple daily injections in brittle diabetic patients.
    Barbosa J; Menth L; Eaton J; Sutherland D; Freier EF; Najarian J
    Diabetes Care; 1981; 4(2):269-74. PubMed ID: 7011745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.